ArticleSurgical endoscopy2026
Incidence of de novo gastroesophageal reflux disease following sleeve gastrectomy versus sleeve gastrectomy with transit bipartition: a retrospective cohort study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSleeve gastrectomy (SG) is the most commonly performed bariatric procedure worldwide; however, concerns persist regarding the development of de novo gastroesophageal reflux disease (GERD) after surgery. Sleeve gastrectomy with transit bipartition (SG-TB) has emerged as a potential alternative, aiming to reduce GERD incidence while achieving superior weight loss outcomes. This study aimed to compare short-term outcomes of GERD, weight loss, and perioperative safety between SG and SG-TB.
methodsA retrospective cohort study was conducted with 215 patients who underwent SG (n = 100) or SG-TB (n = 115) between January and December 2022. Eligible patients were aged 16-65 years with a body mass index (BMI) of ≥ 27.5 kg/m
resultsAt 12 months, the SG-TB group demonstrated superior weight loss (%EWL: 112.0 ± 38.2% vs. 97.2 ± 25.5%, p = 0.001; %TWL: 33.8 ± 7.4% vs. 31.1 ± 6.4%, p = 0.006). The incidence of GERD was significantly lower in the SG-TB group (7.0% vs. 29.0%, p < 0.001). Multivariate regression analysis identified SG as an independent risk factor for developing de novo GERD postoperatively (OR 4.536, 95% CI 1.787-11.519, p = 0.001). SG-TB was associated with longer operative time but showed comparable early postoperative safety to SG.
conclusionsSG-TB significantly reduced the risk of postoperative GERD and resulted in superior short-term weight loss compared to SG, without increasing perioperative complication rates. Further multicenter, long-term studies are needed to validate these findings.
Indexed as
Identifiers
41042344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.